ALK-001 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
301	黄斑ジストロフィー	3

301. 黄斑ジストロフィー

臨床試験数 : 46 / 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04239625 (ClinicalTrials.gov)	December 20, 2019	11/1/2020	Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease	Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	Drug: ALK-001	Alkeus Pharmaceuticals, Inc.	NULL	Enrolling by invitation	8 Years	70 Years	All	140	Phase 2	United States
2	NCT02402660 (ClinicalTrials.gov)	August 2015	9/3/2015	Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease	Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	Drug: ALK-001;Drug: Placebo	Alkeus Pharmaceuticals, Inc.	NULL	Recruiting	8 Years	70 Years	All	140	Phase 2	United States
3	NCT02230228 (ClinicalTrials.gov)	April 2014	27/8/2014	Phase 1 Safety Study of ALK-001 in Healthy Volunteers	A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers	Stargardt Disease;Age-related Macular Degeneration;Other Retinal Dystrophies	Drug: ALK-001 (No generic name)	Alkeus Pharmaceuticals, Inc.	NULL	Completed	21 Years	70 Years	Both	40	Phase 1	NULL